We are live on ! Find out more
OMIC

Singular Genomics Systems, Inc. Common Stock

Delisted

OMIC was delisted on the 20th of February, 2025.

80 hedge funds and large institutions have $74.8M invested in Singular Genomics Systems, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 23 increasing their positions, 21 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 12

8% more funds holding

Funds holding: 7480 (+6)

10% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 21

25% less capital invested

Capital invested by funds: $99.2M → $74.8M (-$24.4M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
80
Holders Change
+6
Holders Change %
+8.11%
% of All Funds
1.29%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
19
Increased
23
Reduced
21
Closed
12
Calls
$10K
Puts
Net Calls
+$10K
Net Calls Change
+$10K
Name Holding Trade Value Shares
Change
Change in
Stake
DM
1
Deerfield Management
New York
$13M -$1.4M -20,905 -9%
UBS Group
2
UBS Group
Switzerland
$9.45M +$55.9K +834 +0.5%
AVM
3
Arch Venture Management
Illinois
$7.64M
BlackRock
4
BlackRock
New York
$7.14M -$430K -6,413 -5%
PA
5
Perceptive Advisors
New York
$6.6M -$567K -8,467 -7%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$4.28M +$9.32K +139 +0.2%
Coatue Management
7
Coatue Management
New York
$4.26M
Vanguard Group
8
Vanguard Group
Pennsylvania
$4.25M +$529K +7,895 +13%
CC
9
Casdin Capital
New York
$2.7M
State Street
10
State Street
Massachusetts
$1.79M +$172K +2,572 +10%
PIM
11
Platinum Investment Management
Australia
$1.77M
Goldman Sachs
12
Goldman Sachs
New York
$1.77M -$136K -2,029 -6%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$1.74M +$45.6K +680 +2%
O
14
OrbiMed
New York
$1.09M
Northern Trust
15
Northern Trust
Illinois
$954K -$15.7K -235 -1%
TM
16
Tikvah Management
North Carolina
$637K -$2.23M -33,333 -76%
BCM
17
Bridgeway Capital Management
Texas
$457K +$482K +7,186 +1,810%
OMC
18
Oasis Management Company
Cayman Islands
$446K
N
19
Nuveen
North Carolina
$442K -$42.1K -628 -8%
HighTower Advisors
20
HighTower Advisors
Illinois
$398K -$22.6K -337 -5%
AFM
21
Anson Funds Management
Texas
$341K +$379K +5,658 New
Bank of New York Mellon
22
Bank of New York Mellon
New York
$340K +$43.8K +654 +13%
TM
23
Triatomic Management
California
$312K -$173K -2,574 -33%
Charles Schwab
24
Charles Schwab
California
$302K +$13K +194 +4%
Morgan Stanley
25
Morgan Stanley
New York
$219K +$14.7K +220 +6%

OMIC Hedge Fund Activity: Q4 2022 in Review

80 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Singular Genomics Systems, Inc. Common Stock (OMIC) for Q4 2022, worth a combined $74.8M — down 25% from $99.2M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new OMIC positions and 12 closed out — a net gain of 7 holders — while 23 added to existing stakes and 21 trimmed.

The largest buyer was Vanguard Group, adding an estimated $529K. The largest seller was Tikvah Management, cutting an estimated $2.23M.

  • 80 institutional investors held Singular Genomics Systems, Inc. Common Stock (OMIC) as of Q4 2022, up from 74 in Q3 2022.
  • Funds reported $74.8M of Singular Genomics Systems, Inc. Common Stock stock for Q4 2022, down 25% quarter-over-quarter.
  • 19 funds opened new Singular Genomics Systems, Inc. Common Stock positions in Q4 2022 and 12 closed out, a net change of +7 holders.
  • The largest Singular Genomics Systems, Inc. Common Stock buyer in Q4 2022 was Vanguard Group, an estimated $529K added.
  • The largest Singular Genomics Systems, Inc. Common Stock seller in Q4 2022 was Tikvah Management, an estimated $2.23M sold.

Based on aggregated 13F filings for Q4 2022.